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Natural killer (NK) cells are characterized by their ability to detect and induce apop-
tosis of susceptible target cells and by secretion of immunoregulatory cytokines such 
as IFN-γ. Activation of these effector functions is triggered upon recognition of tumor 
and pathogen (mostly virus)-infected cells and because of a bidirectional cross talk that 
NK cells establish with other cells of myeloid origin such as dendritic cells (DC) and 
macrophages. A common characteristic of these myeloid cells is their ability to secrete 
different members of the IL-12 family of cytokines such as IL-12, IL-23, and IL-27 and 
cytokines such as IL-15 and IL-18. Although the effect of IL-12, IL-15, and IL-18 has 
been characterized, the effect of IL-23 and IL-27 on NK cells (especially human) remains 
ill-defined. Particularly, IL-27 is a cytokine with dual functions as it has been described 
as pro- and as anti-inflammatory in different experimental settings. Recent evidence 
indicates that this cytokine indeed promotes human NK cell activation, IFN-γ secre-
tion, NKp46-dependent NK cell-mediated cytotoxicity, and antibody (Ab)-dependent 
NK cell-mediated cytotoxicity (ADCC) against monoclonal Ab-coated tumor cells. 
Remarkably, IL-27 also primes NK cells for IL-18 responsiveness, enhancing these 
functional responses. Consequently, IL-27 acts as a pro-inflammatory cytokine that, in 
concert with other DC-derived cytokines, hierarchically contributes to NK cells activation 
and effector functions, which likely contributes to foster the adaptive immune response 
in different physiopathological conditions.
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inTRODUCTiOn
Natural killer (NK) cells constitute one of the three major lymphoid cell populations in blood. They 
play a protective role against viral infections and tumors, although additional evidence indicates that 
NK cells are also key players during immunity against other intracellular pathogens (1, 2). In humans, 
evidence about their role during viral infections came from the observation that patients with rare 
primary immunodeficiencies that lead to the absence of NK cells or the presence of dysfunctional 
NK cells display increased susceptibility to different viruses (3, 4). Currently, we know that the 
relevance of NK cells in immunity goes far beyond viral infections, being active immunoregulatory 
cells during infections with other pathogens, and also during autoimmune processes and in allograft 
rejection (1). Moreover, it has been established that NK cells are abundant in different tissues where 
they may exert such functions, in particular, immunosurveillance against pathogens (5, 6).
From a functional aspect, human and mouse NK cells share the ability to induce apoptosis of 
susceptible target cells through the secretory and death receptor-mediated pathways (FasL and 
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TRAIL) as well as the capacity to secrete immunoregulatory 
cytokines (7). Nevertheless, phenotypic characterization of NK 
cells in both species is quite different. In mice, NK cells are mostly 
identified as CD3− CD49b+ cells, although in C57BL/6 mice but 
they can also be characterized as CD3−CD161b/CD161c+ cells 
(better known as CD3−NK1.1+ cells) (2, 8). In humans, NK cells 
are characterized as CD3−CD56+ cells but can be subdivided into 
different subpopulations based on a differential expression of 
CD56 and CD16 (9, 10). The majority of peripheral blood NK 
cells (about a 90%) are CD3−CD56dimCD16+, which display a 
high content of perforin and granzymes and a strong cytotoxic 
activity, while the rest of NK cells in blood are CD3−CD56bright 
CD16dim/− and produce immunoregulatory cytokines in response 
to different stimuli (11, 12). This subpopulation of NK cells is 
highly abundant in second lymph organs, where they instruct 
dendritic cells (DC) to promote Th1- and cytotoxic CD8 T cell-
biased responses, shaping in this way the adaptive immunity 
(13, 14). Some evidence suggests that CD56brightCD16dim/− can 
differentiate into CD56dimCD16+ cells upon in vitro stimulation, 
indicating that they may constitute developmental stages of fully 
mature CD56dimCD16+ NK cells (15–17). NK cell subpopulations 
also express different chemokine receptors involved in their hom-
ing to different anatomical niches (5, 18).
Recently, identification of innate immune lymphoid cell 
populations (ILC), especially in mucosal sites, led to a reclas-
sification of NK cells as members of this extended family of cells 
of the innate immune response (19–22). ILC contribute to tissue 
homeostasis, and they seem to be important players of immunity 
in mucosal sites. Three groups of ILC populations have been 
described (ILC1, ILC2, and ILC3), which differ in their transcrip-
tional, phenotypic, and transcriptional signatures, respectively 
(19, 21, 22). Moreover, ILC phenotype and function mirrors the 
phenotype and function of T cells, indicating that innate immune 
cells display a similar functional compartmentalization as occurs 
with adaptive immune cells. NK cells have been classified as a 
subgroup of ILC1, suggesting that they could be some sort of 
ancestors or innate counterparts of T helper 1 and cytotoxic 
T lymphocyte (CTL) cells (19, 21, 22). Although all ILC1 express 
T-bet, respond to IL-12 and IL-15 and share the ability to produce 
IFN-γ, only NK cells express EOMES, which differentiates them 
from other ILC1 populations (19, 21, 22).
A vast array of surface receptors confer NK cells the ability 
to sense their environment. Direct recognition of target cells 
through inhibitory and activating receptors is a critical event that 
determines activation of NK cell-mediated cytotoxicity against 
susceptible cells (virus-infected or neoplastic cells), preserving 
healthy cells from such response (7). Many receptors that recog-
nize discrete ligands expressed on target cells and that trigger NK 
cell activation or promote inhibition of NK cell-mediated effec-
tor functions have been identified and cloned (2, 10). The better 
characterized receptors that regulate target cell recognition and 
activation by NK cells are CD16 or FcRγIII [which mediates anti-
body (Ab)-recognition of target cells and triggers Ab-dependent 
cell-mediated cytotoxicity or ADCC], CD314 or NKG2D, the 
natural cytotoxicity receptors CD335 (NKp46), CD336 (NKp44) 
and CD337 (NKp30), CD226 (DNAM-1), CD244 (2B4), mem-
bers of the CD158 or killer immunoglobulin-like receptor (KIR) 
family that carry a short cytoplasmic tail (KIR2DS and KIR3DS) 
and CD94/NKG2C, among others (2, 10, 23). Conversely, inhibi-
tory receptors that preclude NK cell activation are members of the 
CD158 or KIR family that carry a long cytoplasmic tail (KIR2DL 
and KIR3DL), CD94/NKG2A, TIGIT, and CD85j (ILT-2, LILRB1, 
or LIR-1), among others (2, 10, 23).
Natural killer cells not only sense and respond to ligands 
expressed on the cell surface of target cells. Instead, functional 
response of NK cells also depends on recognition of soluble 
factors such as pro-inflammatory cytokines (24). Nonetheless, 
other soluble factors also exert immunoregulatory functions on 
these cells. We and others (25–30) observed that NK cells express 
endosomal toll-like receptors (TLRs) and respond to specific 
agonists. In particular, human NK cells express functional TLR3, 
TLR7, and TLR9, and stimulation of NK cells with their agonists 
triggers IFN-γ secretion only in the presence of suboptimal 
concentrations of IL-12 or IFN-α but not IL-15 (25). This effect 
was further potentiated by co-engagement of NKG2D, one of the 
major cell surface receptors involved in recognition and elimina-
tion of tumor cells by NK cells, but TLR agonists do not seem 
to exert immunoregulatory effects on NKG2D-dependent NK 
cell-mediated cytotoxicity (5). Therefore, NK cells can sense and 
integrate signals derived from their surrounding environment, 
and that are detected by different categories of receptors.
Biological functions of NK cells are tightly regulated during 
their interaction with DC as a consequence of which NK cells 
promote maturation of DC and become activated by cell surface 
receptors such as NKp30 (31) and DNAM-1 (32) and cytokines 
such as IL-12, IL-15, and IL-18 (9, 13, 31–35). Remarkably, the 
consequences of this interaction are not only manifested in NK 
cells but also impact on the adaptive immunity as NK cells pro-
mote maturation of DC and instruct them to shape T cell activa-
tion toward Th1- and CTL-mediated responses (13, 14, 31, 33).
In this context, an integral analysis of factors that regulate 
NK cell effector functions may contribute to the development 
of novel strategies to improve immunosurveillance and promote 
a sustained tumoricidal capacity of NK cells (7). Therefore, the 
focus of our laboratory has been the investigation of how NK cells 
sense their environment and unravel novel factors that affect their 
phenotype and functions.
ReGULATiOn OF nK CeLL ACTivATiOn 
AnD eFFeCTOR FUnCTiOnS BY iL-27
IL-12 is the first described member of an extended family of 
cytokines produced mostly by myeloid cells (DC and mac-
rophages) in response to infectious agents and other insults (36). 
IL-12 promotes the generation of Th1, IFN-γ-producing cells 
during naive CD4+ T cell activation (37). Also, IL-12 produced by 
macrophages triggers NK cell-mediated IFN-γ production dur-
ing infection with intracellular parasites (38) and contributes to 
protection during acute infection (39). These findings unraveled 
the existence of a cytokine axis in which myeloid cell-derived 
IL-12 triggers lymphoid cell-derived IFN-γ production and 
contributes to resistance to infection.
Members of the IL-12 family of heterodimeric cytokines 
share protein subunits and receptor chains. IL-12 is composed 
FiGURe 1 | Summary of cytokine axis involving iL-27 in human natural 
killer (nK) cell activation. Mature DC (mDC) secrete IL-12, IL-27, and 
IL-18, among others. During the cross talk between mDC and NK cells (and 
besides the known effect of IL-12), IL-27, alone or in concert with IL-18, 
triggers NK cell activation (upregulation of CD25 and CD69), IFN-γ 
production, and cytotoxicity against target cells that are otherwise resistant to 
non-stimulated NK cells. Such cytotoxic response involves recognition of 
target cells through NKp46- and CD16-dependent mechanisms (ADCC) and 
induction of target cell apoptosis via granule exocytosis and TRAIL-mediated 
mechanisms. Moreover, IL-27 also primes NK cells for IL-18-mediated 
augmented IFN-γ secretion which in turn upregulates ICAM-1 on target cells, 
facilitates the formation of NK cell–target cell conjugates, and therefore 
further increases the cytotoxic activity of NK cells. Since IL-18 primes NK 
cells for IL-12 responsiveness, IL-27-driven priming of NK cells for IL-18 may 
also contribute to further potentiate IL-12 responsiveness and fostering NK 
cell effector functions.
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by two subunits, namely, p35 and p40, and is recognized by a 
heterodimeric receptor composed of two chains IL-12Rβ1 and 
IL-12Rβ2 (36). Signaling through this receptor activates mainly 
STAT4, activates T-bet, and leads to IFN-γ production in NK 
and T cells, thus mediating pro-inflammatory effects (40–42). 
Since naïve T cells do not express IL-12Rβ2, IL-12 alone does 
not seem to be sufficient to guide T cell activation toward Th1 
cells (43). A similar effect was described for IFN-γ production 
by human and mouse NK cells (25, 44–46), suggesting that IL-12 
requires a cooperation with other factors to properly exert its 
effects on NK and T cell-derived IFN-γ production. IL-12 also 
enhances NK cell-mediated cytotoxicity against different target 
cells, affects expression of some cell surface receptors involved in 
target cell recognition (47–49), and, more recently, IL-12 has also 
been involved in the generation of memory-like NK cells (50, 51). 
IL-12 is secreted by DC and macrophages and has been shown to 
be a major player of a bidirectional cross talk that they establish 
with NK or T cells (36). Also, as a consequence of their cross talk 
with macrophages, NK cells can stimulate production of nitric 
oxide (NO) due to upregulation of inducible NO synthase (52). 
In addition, as a consequence of their cross talk with DC, NK 
cells can promote upregulation of costimulatory molecules such 
as CD86 (53).
Other members of the IL-12 family of cytokines are IL-23, 
IL-27, and IL-35 (36, 54) which, as mentioned, are heterodimeric 
proteins that share not only one subunit with another member of 
the family but also signal through heterodimeric receptors with 
shared subunits (54, 55). As with IL-12, macrophages and DC 
can produce IL-23 and IL-27 upon sensing pathogens or their 
products (56–59). IL-23 is composed by one subunit shared with 
IL-12 (p40) that is associated with the p19 subunit to constitute 
the active form of IL-23. This cytokine signals through a heter-
odimeric receptor composed of IL-12Rβ1 and IL-23R, which 
activates Jak2/Tyk2, STAT1/STAT3/STAT4/STAT5 (60). IL-23 
activates NK cells and in this way, contributes to the antitumor 
immune response (61, 62). Nevertheless, other authors failed to 
demonstrate an effect of IL-23 on NK cells (63, 64), making the 
effects of this cytokine on NK cells an open question that warrants 
further investigation.
IL-27, in turn, is a heterodimeric cytokine composed by the 
EBI3 and p28 subunits that signals through a heterodimeric 
receptor composed by the WSX-1 and CD130/gp130 chains 
(54, 55, 65, 66). As with other members of this familty of 
cytokines, IL-27 is produced mainly by DC and macrophages 
upon microbial insults (55). Paradoxically, IL-27 displays pro- 
and anti-inflammatory functions due to activation of STAT1 
and STAT3, respectively (36), but its pro-inflammatory effects 
depend on induction of T-bet and IL-12Rβ2 expression (67–69). 
In line with a dual role of IL-27, it has been shown that this 
cytokine prevents tissue damage induced by excessive inflam-
mation (54, 70). The effect of IL-27 on NK cells and their ability 
to control tumor growth have been described in some mouse 
models (63, 70–76), while in other tumor models, an effect of 
IL-27 on NK cells was not observed (77). Therefore, the effects 
of IL-27 on mouse NK cells might be tumor-type dependent. 
In humans, it was reported that IL-27 can costimulate NK cells 
for IFN-γ gene expression (78), while we observed that mature 
DC secrete IL-27 and that this cytokine contributes to NK cell 
activation and effector functions (79). Indeed, IL-27 can directly 
trigger IFN-γ secretion through activation of STAT1 and pro-
mote activation of NK cells (upregulation of CD25 and CD69). 
IL-27 also promotes upregulation of NKp46 and subsequent 
NKp46-dependent NK cell-mediated cytotoxicity against target 
cells that are otherwise resistant to NK cell-mediated cytotoxic-
ity, through the secretory pathway and TRAIL (79). IL-27 also 
potentiates ADCC induced by therapeutic monoclonal antibod-
ies such as rituximab, trastuzumab, and cetuximab, suggesting 
that IL-27 may be helpful as adjuvant during immunotherapy 
in human patients (79). The effects of IL-27 on NK cells are 
summarized in Figure 1.
COOPeRATiOn BeTween CYTOKineS 
FOR nK CeLL STiMULATiOn: THe CASe 
OF iL-27 AnD iL-18
Cooperative effect of cytokines, in particular those secreted by 
DC and macrophages, has been described for many of them 
and reviewed elsewhere (24). Briefly, cooperative effects of 
IL-12 and IL-2 or IL-15 (80, 81), IL-2 and IL-15 (82), IL-12 
4Zwirner and Ziblat IL-27 and NK cells
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and IL-18 (81, 83–85) for NK cell activation, IFN-γ production, 
and cytotoxicity have been described. In most cases, underly-
ing mechanisms of cytokine cooperation for NK cell activation 
remain ill-defined. IL-18 belongs to the IL-1 superfamily and 
has the peculiarity of having a critical effect on NK cells (86). 
IL-18 seems to play a major role as “cooperating cytokine” 
for NK cell activation and elicitation of effector functions 
(87, 88). Accordingly, NK cells from IL-18−/− mice display a 
deep impaired immune response against tumors and cannot 
be properly stimulated in  vivo with IL-12 to secrete IFN-γ 
(89). These and other experimental results led to the notion 
that IL-18 actually primes NK cells to become responsive to 
IL-12 (89–91). Remarkably, we demonstrated that IL-27 also 
primes NK cells but for IL-18-mediated IFN-γ secretion induc-
ing upregulation of T-bet expression in NK cells (79). T-bet 
is a critical transcription factor that regulates IFN-γ produc-
tion (92, 93) by promoting IFN-γ gene transcription (94). 
Moreover, cooperation between IL-27 and IL-18 enhances NK 
cell-mediated cytotoxicity through the secretory pathway and 
TRAIL and involves NK cell-derived IFN-γ. This is because 
IFN-γ secretion during effector–target cell contact increases 
the percentage of ICAM-1+ target cells that in turn facilitates 
the formation of NK cell–target cell conjugates and delivery of 
the cytotoxic hit (95). These effects are summarized in Figure 1.
As DC and macrophages stimulated with microbial products 
or tumor cells can secrete IL-12, IL-18, and IL-27 (36, 73), it is 
possible that stimulatory effects of IL-27 may occur when DC or 
macrophages secrete this cytokine and establish a bidirectional 
cross talk with NK cells. During this cross talk, IL-27 may prime 
NK cells for IL-18 responsiveness, while IL-18 secreted at the 
synaptic cleft between NK cells and DC (91) may in turn prime 
NK cells for IL-12 responsiveness (90). Although a kinetic 
analysis of the production of these cytokines needs to be per-
formed to establish the temporal relationship in their secretion, 
the cooperation between IL-27 and IL-18 that we described 
unravels the existence of a hierarchical cytokine network that 
is relevant during DC-NK cell cross talk that generates fully 
functional NK cells. In line with this hierarchical cytokine 
network in NK cell activation is the fact that IL-27 can initiate 
Th1 development by naïve T cells by promoting activation of 
STAT1 and STAT3, expression of T-bet, repression of GATA3 
(involved in Th2 differentiation), and production of IL-12Rβ2 
chain (67, 68, 96, 97). These changes in CD4 T cells during 
activation confer them the ability to sense DC-derived IL-12 
and consequently follow the path of Th1 differentiation, leading 
to secretion of IFN-γ.
Collectively, the cytokine axis composed of IL-27/IL-18/IL-12 
is indeed involved in optimal NK cell activation and in skewing 
CD4 T cell responses through a cross talk between these lymphoid 
cells (NK cells and T cells) and myeloid cells (DC), representing 
an important link between innate and adaptive immunity.
COnCLUDinG ReMARKS
Natural killer cells are currently viewed not only as cytotoxic cells 
but also as strong producers of immunoregulatory cytokines, in 
particular, IFN-γ. They belong to the family of ILC, and their 
effector functions are tightly regulated by interaction with DC 
and other cells of myeloid lineage, which secrete cytokines with 
NK cell-stimulating activity. IL-12 is one of the most relevant 
cytokines produced by myeloid cells that promote NK cell 
activation. The discovery of other members of the IL-12 family 
of cytokines, such as IL-23 and IL-27, and exploration of coopera-
tion between cytokines for NK cell activation have established 
that NK cells also become activated by IL-27. Interestingly, IL-27 
not only exerts direct effects on NK cells but also primes them for 
IL-18-responsiveness, which unveils another aspect of the intri-
cate cytokine network that regulates NK cell biological functions 
and that further demonstrates a hierarchical effect of different 
cytokines on these cells. Consequently, NK cells display the 
ability to integrate multiple signals from their environment and 
adjust their effector functions accordingly, probably to optimize 
the magnitude of their response to pathogens and tumor cells 
and shape adaptive immunity in different physiopathological 
conditions.
AUTHOR COnTRiBUTiOnS
NZ designed and wrote the review and prepared the figures. AZ 
revised the manuscript and figures.
ACKnOwLeDGMenTS
The authors would like to thank to past and current lab members. 
This work was supported by grants from the National Agency for 
Promotion of Science and Technology from Argentina (ANPCYT), 
the National Research Council of Argentina (CONICET), and the 
University of Buenos Aires (UBA), all to NZ. The authors also 
thank to Fundación Williams and Fundación René Barón for 
providing financial assistance (donations) to their laboratory. NZ 
is a member of the Researcher Career of CONICET and professor 
at UBA. AZ is a postdoctoral fellow of CONICET.
ReFeRenCeS
1. Newman KC, Riley EM. Whatever turns you on: accessory-cell-dependent 
activation of NK cells by pathogens. Nat Rev Immunol (2007) 7(4):279–91. 
doi:10.1038/nri2057 
2. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. 
Nat Immunol (2008) 9(5):495–502. doi:10.1038/ni1581 
3. Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer 
R, et  al. Deficient natural killer cell cytotoxicity in patients with IKK- 
gamma/NEMO mutations. J Clin Invest (2002) 109(11):1501–9. doi:10.1172/ 
JCI14858 
4. Orange JS. Unraveling human natural killer cell deficiency. J Clin Invest (2012) 
122(3):798–801. doi:10.1172/JCI62620 
5. Carrega P, Ferlazzo G. Natural killer cell distribution and trafficking in human 
tissues. Front Immunol (2012) 3:347. doi:10.3389/fimmu.2012.00347 
6. Melsen JE, Lugthart G, Lankester AC, Schilham MV. Human circulating and 
tissue-resident CD56(bright) natural killer cell populations. Front Immunol 
(2016) 7:262. doi:10.3389/fimmu.2016.00262 
7. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new 
tricks. Nat Rev Cancer (2016) 16(1):7–19. doi:10.1038/nrc.2015.5 
8. Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr 
Opin Immunol (2016) 39:82–9. doi:10.1016/j.coi.2016.01.007 
5Zwirner and Ziblat IL-27 and NK cells
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 25
9. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused 
tissues. Nat Rev Immunol (2002) 2(12):957–64. doi:10.1038/nri956 
10. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the 
interface between innate and adaptive immunity. Cell Death Differ (2008) 
15(2):226–33. doi:10.1038/sj.cdd.4402170 
11. Caligiuri MA. Human natural killer cells. Blood (2008) 112(3):461–9. 
doi:10.1182/blood-2007-09-077438 
12. Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: direct 
pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 
180(12):7785–91. doi:10.4049/jimmunol.180.12.7785 
13. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, et al. Distinct 
roles of IL-12 and IL-15 in human natural killer cell activation by dendritic 
cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 
101(47):16606–11. doi:10.1073/pnas.0407522101 
14. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. The 
abundant NK cells in human secondary lymphoid tissues require activation 
to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 
172(3):1455–62. doi:10.4049/jimmunol.172.3.1455 
15. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. 
CD56bright human NK cells differentiate into CD56dim cells: role of contact 
with peripheral fibroblasts. J Immunol (2007) 179(1):89–94. doi:10.4049/
jimmunol.179.1.89 
16. Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, et al. 
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres 
and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 
178(8):4947–55. doi:10.4049/jimmunol.178.8.4947 
17. Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell 
development and terminal differentiation. Front Immunol (2013) 4:499. 
doi:10.3389/fimmu.2013.00499 
18. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique 
subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes 
identified by chemokine receptor expression repertoire. J Immunol (2001) 
166(11):6477–82. doi:10.4049/jimmunol.166.11.6477 
19. Cella M, Miller H, Song C. Beyond NK cells: the expanding universe of innate 
lymphoid cells. Front Immunol (2014) 5:282. doi:10.3389/fimmu.2014.00282 
20. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate 
lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol 
(2013) 13(2):145–9. doi:10.1038/nri3365 
21. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and 
immunity. Immunity (2014) 41(3):366–74. doi:10.1016/j.immuni.2014.09.006 
22. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diver-
sity of innate lymphoid cells. Immunity (2014) 41(3):354–65. doi:10.1016/j.
immuni.2014.09.005 
23. Bartel Y, Bauer B, Steinle A. Modulation of NK cell function by genetically 
coupled C-type lectin-like receptor/ligand pairs encoded in the human 
natural killer gene complex. Front Immunol (2013) 4:362. doi:10.3389/
fimmu.2013.00362 
24. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector 
functions. Biofactors (2010) 36(4):274–88. doi:10.1002/biof.107 
25. Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW. Engagement of 
TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-
mediated cytotoxicity by human NK cells stimulated with suboptimal 
doses of IL-12. J Immunol (2007) 179(6):3472–9. doi:10.4049/jimmunol. 
179.6.3472 
26. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N’Guyen T, 
et al. Direct bacterial protein PAMP recognition by human NK cells involves 
TLRs and triggers alpha-defensin production. Blood (2004) 104(6):1778–83. 
doi:10.1182/blood-2003-08-2820 
27. Hart OM, Athie-Morales V, O’Connor GM, Gardiner CM. TLR7/8-
mediated activation of human NK cells results in accessory cell-dependent 
IFN-gamma production. J Immunol (2005) 175(3):1636–42. doi:10.4049/
jimmunol.175.3.1636 
28. Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, Moretta L, et al. 
CpG and double-stranded RNA trigger human NK cells by toll-like receptors: 
induction of cytokine release and cytotoxicity against tumors and dendritic 
cells. Proc Natl Acad Sci U S A (2004) 101(27):10116–21. doi:10.1073/
pnas.0403744101 
29. Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, 
et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 
and TLR-8 agonists. Int Immunol (2006) 18(7):1115–26. doi:10.1093/intimm/
dxl046 
30. Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, et al. 
APC-independent activation of NK cells by the toll-like receptor 3 agonist 
double-stranded RNA. J Immunol (2004) 172(1):138–43. doi:10.4049/
jimmunol.172.1.138 
31. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human 
dendritic cells activate resting natural killer (NK) cells and are recognized via 
the NKp30 receptor by activated NK cells. J Exp Med (2002) 195(3):343–51. 
doi:10.1084/jem.20011149 
32. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, 
Dondero A, et  al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) 
and poliovirus receptor (CD155), on dendritic cells: relevance for natural 
killer-dendritic cell interaction. Blood (2006) 107(5):2030–6. doi:10.1182/ 
blood-2005-07-2696 
33. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia 
A, et  al. Induced recruitment of NK cells to lymph nodes provides IFN-
gamma for T(H)1 priming. Nat Immunol (2004) 5(12):1260–5. doi:10.1038/ 
ni1138 
34. Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, 
et  al. NK cell-mediated lysis of autologous antigen-presenting cells is 
triggered by the engagement of the phosphatidylinositol 3-kinase upon 
ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur 
J Immunol (2001) 31(6):1656–65. doi:10.1002/1521-4141(200106)31:6<1656: 
AID-IMMU1656>3.0.CO;2-V 
35. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and 
dendritic cells: “l’union fait la force”. Blood (2005) 106(7):2252–8. doi:10.1182/
blood-2005-03-1154 
36. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. 
Nat Immunol (2012) 13(8):722–8. doi:10.1038/ni.2366 
37. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ 
T cells to enhance priming for interferon gamma production and diminishes 
interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A (1993) 
90(21):10188–92. doi:10.1073/pnas.90.21.10188 
38. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required 
for the T-lymphocyte-independent induction of interferon gamma by 
an intracellular parasite and induces resistance in T-cell-deficient hosts. 
Proc Natl Acad Sci U S A (1993) 90(13):6115–9. doi:10.1073/pnas.90. 
13.6115 
39. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, 
et  al. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and 
resistance during acute infection with Toxoplasma gondii. J Immunol (1994) 
153(6):2533–43. 
40. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell 
JE Jr, et  al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves 
tyrosine phosphorylation of signal transducer and activator of transcription 
(Stat)3 and Stat4. J Exp Med (1995) 181(5):1755–62. doi:10.1084/jem.181. 
5.1755 
41. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, 
Carson RT, et al. Requirement for Stat4 in interleukin-12-mediated responses 
of natural killer and T cells. Nature (1996) 382(6587):171–4. doi:10.1038/ 
382171a0 
42. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and 
enhanced development of Th2 cells in Stat4-deficient mice. Nature (1996) 
382(6587):174–7. doi:10.1038/382174a0 
43. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin 
(IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 
cells. J Exp Med (1997) 185(5):817–24. doi:10.1084/jem.185.5.817 
44. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew 
FY, et  al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and 
IL-15 regulation of NK cell responses to viral infection. J Immunol (2002) 
169(8):4279–87. doi:10.4049/jimmunol.169.8.4279 
45. Andoniou CE, van Dommelen SL, Voigt V, Andrews DM, Brizard G, Asselin-
Paturel C, et al. Interaction between conventional dendritic cells and natural 
killer cells is integral to the activation of effective antiviral immunity. Nat 
Immunol (2005) 6(10):1011–9. doi:10.1038/ni1244 
46. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high 
stage and effector functions. J Immunol (2004) 172(1):88–96. doi:10.4049/
jimmunol.172.1.88 
6Zwirner and Ziblat IL-27 and NK cells
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 25
47. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, 
et al. Differential antitumor effects of administration of recombinant IL-18 or 
recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin- 
induced tumor apoptosis, respectively. J Immunol (1999) 163(2):583–9. 
48. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, 
et  al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-met-
astatic effect of IL-12. Eur J Immunol (1999) 29(4):1390–6. doi:10.1002/
(SICI)1521-4141(199904)29:04<1390:AID-IMMU1390>3.0.CO;2-C 
49. Orange JS, Wang B, Terhorst C, Biron CA. Requirement for natural killer 
cell-produced interferon gamma in defense against murine cytomegalovirus 
infection and enhancement of this defense pathway by interleukin 12 adminis-
tration. J Exp Med (1995) 182(4):1045–56. doi:10.1084/jem.182.4.1045 
50. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. 
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 
(2009) 106(6):1915–9. doi:10.1073/pnas.0813192106 
51. O’Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity (2015) 
43(4):634–45. doi:10.1016/j.immuni.2015.09.013 
52. Yang J, Kawamura I, Zhu H, Mitsuyama M. Involvement of natural killer cells 
in nitric oxide production by spleen cells after stimulation with Mycobacterium 
bovis BCG. Study of the mechanism of the different abilities of viable and 
killed BCG. J Immunol (1995) 155(12):5728–35. 
53. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. 
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal 
requirement for the induction of NK cell helper function. J Immunol (2003) 
171(5):2366–73. doi:10.4049/jimmunol.171.5.2366 
54. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and 
IL-27: related but functionally distinct regulators of inflammation. Annu 
Rev Immunol (2007) 25:221–42. doi:10.1146/annurev.immunol.22.012703. 
104758 
55. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, 
a heterodimeric cytokine composed of EBI3 and p28 protein, induces prolif-
eration of naive CD4(+) T cells. Immunity (2002) 16(6):779–90. doi:10.1016/
S1074-7613(02)00324-2 
56. de Groot R, van Beelen AJ, Bakdash G, Taanman-Kueter EW, de Jong EC, 
Kapsenberg ML. Viral dsRNA-activated human dendritic cells produce IL-27, 
which selectively promotes cytotoxicity in naive CD8+ T cells. J Leukoc Biol 
(2012) 92(3):605–10. doi:10.1189/jlb.0112045 
57. Molle C, Nguyen M, Flamand V, Renneson J, Trottein F, De Wit D, et al. IL-27 
synthesis induced by TLR ligation critically depends on IFN regulatory factor 
3. J Immunol (2007) 178(12):7607–15. doi:10.4049/jimmunol.178.12.7607 
58. Iyer SS, Ghaffari AA, Cheng G. Lipopolysaccharide-mediated IL-10 trans-
criptional regulation requires sequential induction of type I IFNs and 
IL-27 in macrophages. J Immunol (2010) 185(11):6599–607. doi:10.4049/
jimmunol.1002041 
59. Pirhonen J, Siren J, Julkunen I, Matikainen S. IFN-alpha regulates toll-like 
receptor-mediated IL-27 gene expression in human macrophages. J Leukoc 
Biol (2007) 82(5):1185–92. doi:10.1189/jlb.0307157 
60. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A recep-
tor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a 
novel cytokine receptor subunit, IL-23R. J Immunol (2002) 168(11):5699–708. 
doi:10.4049/jimmunol.168.11.5699 
61. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, 
et al. Induction of potent antitumor immunity by intratumoral injection of 
interleukin 23-transduced dendritic cells. Cancer Res (2006) 66(17):8887–96. 
doi:10.1158/0008-5472.CAN-05-3448 
62. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic 
administration of IL-23 induces potent antitumor immunity primarily 
mediated through Th1-type response in association with the endogenously 
expressed IL-12. J Immunol (2007) 178(12):7571–80. doi:10.4049/jimmunol. 
178.12.7571 
63. Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, et  al. Expression of 
interleukins-23 and 27 leads to successful gene therapy of hepatocellular car-
cinoma. Mol Immunol (2009) 46(8–9):1654–62. doi:10.1016/j.molimm.2009. 
02.025 
64. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, et  al. Antitumor and 
antimetastatic activity of IL-23. J Immunol (2003) 171(2):600–7. doi:10.4049/
jimmunol.171.2.600 
65. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev 
Immunol (2015) 33:417–43. doi:10.1146/annurev-immunol-032414-112134 
66. Aparicio-Siegmund S, Garbers C. The biology of interleukin-27 reveals unique 
pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor 
Rev (2015) 26(5):579–86. doi:10.1016/j.cytogfr.2015.07.008 
67. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. 
Role of IL-27/WSX-1 signaling for induction of T-bet through activation of 
STAT1 during initial Th1 commitment. J Immunol (2003) 170(10):4886–90. 
doi:10.4049/jimmunol.170.10.4886 
68. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness 
of naive CD4+ T cells through Stat1-dependent and -independent mech-
anisms. Proc Natl Acad Sci U S A (2003) 100(25):15047–52. doi:10.1073/
pnas.2536517100 
69. Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA. IL-27 and IFN-
alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in 
naive T cells. J Interferon Cytokine Res (2003) 23(9):513–22. doi:10.1089/ 
10799900360708632 
70. Wei J, Xia S, Sun H, Zhang S, Wang J, Zhao H, et al. Critical role of dendritic 
cell-derived IL-27 in antitumor immunity through regulating the recruit-
ment and activation of NK and NKT cells. J Immunol (2013) 191(1):500–8. 
doi:10.4049/jimmunol.1300328 
71. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, 
et  al. Interleukin-23 and interleukin-27 exert quite different antitumor 
and vaccine effects on poorly immunogenic melanoma. Cancer Res (2006) 
66(12):6395–404. doi:10.1158/0008-5472.CAN-05-4087 
72. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, et  al. 
Expression of IL-27 in murine carcinoma cells produces antitumor effects and 
induces protective immunity in inoculated host animals. Int J Cancer (2005) 
115(3):437–42. doi:10.1002/ijc.20848 
73. Cocco C, Pistoia V, Airoldi I. Anti-leukemic properties of IL-12, IL-23 and 
IL-27: differences and similarities in the control of pediatric B acute lympho-
blastic leukemia. Crit Rev Oncol Hematol (2012) 83(3):310–8. doi:10.1016/j.
critrevonc.2011.11.006 
74. Liu L, Wang S, Shan B, Shao L, Sato A, Kawamura K, et al. IL-27-mediated acti-
vation of natural killer cells and inflammation produced antitumour effects 
for human oesophageal carcinoma cells. Scand J Immunol (2008) 68(1):22–9. 
doi:10.1111/j.1365-3083.2008.02111.x 
75. Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of 
tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, 
memory precursor-like effector cells. Eur J Immunol (2013) 43(2):468–79. 
doi:10.1002/eji.201242930 
76. Matsui M, Kishida T, Nakano H, Yoshimoto K, Shin-Ya M, Shimada T, et al. 
Interleukin-27 activates natural killer cells and suppresses NK-resistant head 
and neck squamous cell carcinoma through inducing antibody-dependent 
cellular cytotoxicity. Cancer Res (2009) 69(6):2523–30. doi:10.1158/0008-
5472.CAN-08-2793 
77. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, et al. IL-27 
mediates complete regression of orthotopic primary and metastatic murine 
neuroblastoma tumors: role for CD8+ T cells. J Immunol (2004) 173(12):7170–
82. doi:10.4049/jimmunol.173.12.7170 
78. Laroni A, Gandhi R, Beynon V, Weiner HL. IL-27 imparts immunoregula-
tory function to human NK cell subsets. PLoS One (2011) 6(10):e26173. 
doi:10.1371/journal.pone.0026173 
79. Ziblat A, Domaica CI, Spallanzani RG, Iraolagoitia XL, Rossi LE, Avila DE, 
et al. IL-27 stimulates human NK-cell effector functions and primes NK cells 
for IL-18 responsiveness. Eur J Immunol (2015) 45(1):192–202. doi:10.1002/
eji.201444699 
80. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer 
cells identifies a novel mechanism to regulate the innate immune response. 
Blood (1997) 89(3):910–8. 
81. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, 
et al. Differential cytokine and chemokine gene expression by human NK cells 
following activation with IL-18 or IL-15 in combination with IL-12: impli-
cations for the innate immune response. J Immunol (1999) 162(8):4511–20. 
82. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, 
et  al. CD56bright natural killer cells are present in human lymph nodes and 
are activated by T cell-derived IL-2: a potential new link between adaptive 
and innate immunity. Blood (2003) 101(8):3052–7. doi:10.1182/blood-2002- 
09-2876 
83. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, 
et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal 
7Zwirner and Ziblat IL-27 and NK cells
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 25
inflammatory response in mice: critical role of natural killer cell interferon- 
gamma production and STAT-mediated signal transduction. Blood (2000) 
96(4):1465–73. 
84. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, et al. 
NKG2D recognition and perforin effector function mediate effective cytokine 
immunotherapy of cancer. J Exp Med (2004) 200(10):1325–35. doi:10.1084/
jem.20041522 
85. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activa-
tion of natural killer cells by interleukin 12 and interleukin 18. Cytokine (1999) 
11(11):822–30. doi:10.1006/cyto.1999.0501 
86. Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer 
biology and counter-regulation by IL-18BP. J Leukoc Biol (2015) 97(4):665–75. 
doi:10.1189/jlb.5RU0714-360RR 
87. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, 
et  al. Helper role of NK cells during the induction of anticancer responses 
by dendritic cells. Mol Immunol (2005) 42(4):535–9. doi:10.1016/j.
molimm.2004.07.038 
88. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells 
collaborate with dendritic cells to promote recruitment of effector CD8+  
T cells to the tumor microenvironment. Cancer Res (2013) 73(15):4653–62. 
doi:10.1158/0008-5472.CAN-12-4366 
89. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. 
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 
(1998) 8(3):383–90. doi:10.1016/S1074-7613(00)80543-9 
90. Chaix J, Tessmer MS, Hoebe K, Fuseri N, Ryffel B, Dalod M, et al. Priming 
of NK cells by IL-18. J Immunol (2008) 181(3):1627–31. doi:10.4049/
jimmunol.181.3.1627 
91. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in 
IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and 
release of the DC maturation factor HMGB1. Blood (2005) 106(2):609–16. 
doi:10.1182/blood-2004-10-3906 
92. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher 
LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma 
production in CD4 and CD8 T cells. Science (2002) 295(5553):338–42. 
doi:10.1126/science.1065543 
93. Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, et al. Transcriptional 
control of human T-BET expression: the role of Sp1. Eur J Immunol (2007) 
37(9):2549–61. doi:10.1002/eji.200737088 
94. Matsuda JL, George TC, Hagman J, Gapin L. Temporal dissection of T-bet 
functions. J Immunol (2007) 178(6):3457–65. doi:10.4049/jimmunol.178. 
6.3457 
95. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. Natural killer cell-produced 
IFN-gamma and TNF-alpha induce target cell cytolysis through up-reg-
ulation of ICAM-1. J Leukoc Biol (2012) 91(2):299–309. doi:10.1189/jlb. 
0611308 
96. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, 
et  al. Role of T-bet in commitment of TH1 cells before IL-12-dependent 
selection. Science (2001) 292(5523):1907–10. doi:10.1126/science.1059835 
97. Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, et al. T-bet is 
a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat 
Immunol (2002) 3(6):549–57. doi:10.1038/ni794 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Zwirner and Ziblat. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
